Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Sexual-Health

hCG

Human chorionic gonadotropin; Pregnyl; Novarel; Ovidrel (recombinant choriogonadotropin alfa)

Placental glycoprotein hormone (FDA-approved); LH-receptor agonist

This hCG entry draws on 26 cited sources published 1989 to 2026. The evidence available is graded FDA-Approved on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .

At a glance

Class
Placental glycoprotein hormone (FDA-approved); LH-receptor agonist
Drug class
Sexual-Health
Structure
Heterodimeric glycoprotein: α subunit (~92 aa, shared with LH/FSH/TSH) + β subunit (~145 aa, hCG-specific); MW ~36-40 kDa
Route
IM / SC
Half-life
~33 hrs (urine-derived); ~24 hrs (recombinant)
Evidence tier
FDA-Approved
Availability
Prescription
Research depth
243 indexed citations (PubMed 186 · CT 18 · EPMC 39) →

Mechanism of action

LH-receptor agonist with minor FSH-like activity; in males stimulates testicular Leydig cells to produce endogenous testosterone; in females maintains corpus luteum progesterone production and triggers ovulation

Reported areas of research

FDA-approved: female anovulatory infertility / ovulation induction; prepubertal cryptorchidism; selected hypogonadotropic hypogonadism. Off-label clinical use: intratesticular testosterone preservation during exogenous-T therapy; spermatogenesis restoration; HPG restart-stack protocols

Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.

Dosage protocols reported in literature

Female ovulation trigger: 5,000-10,000 USP units IM single dose 1 day after final gonadotropin (FDA Pregnyl/Novarel label). Male off-label: 250 IU SC 2x weekly TRT adjunct (Bhasin Endocrine Society 2018 starting dose, may go higher per response); 1,000 IU IM 2x weekly HPG restart (Crisler protocol starting dose)

Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.

Known concerns and limitations

Ovarian hyperstimulation syndrome (OHSS); thromboembolism; gynecomastia (males at high dose); arterial-thrombosis case reports; contraindicated in suspected/confirmed prostate or other androgen-dependent neoplasia; precocious puberty risk in pediatric use

Compared with

hCG has published head-to-head comparisons with 2 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.

Frequently asked questions

What dosing is reported for hCG in research literature?

Published peptide research reports the following dosing approach for hCG: Female ovulation trigger: 5,000-10,000 USP units IM single dose 1 day after final gonadotropin (FDA Pregnyl/Novarel label). Male off-label: 250 IU SC 2x weekly TRT adjunct (Bhasin Endocrine Society 2018 starting dose, may go higher per response); 1,000 IU IM 2x weekly HPG restart (Crisler protocol starting dose). This is a research reference, not a clinical recommendation.

How is hCG administered in research?

hCG is administered via the following routes in published studies: IM / SC.

What is the reported half-life of hCG?

The reported half-life of hCG is ~33 hrs (urine-derived); ~24 hrs (recombinant).

Is hCG FDA-approved?

Yes. hCG is an FDA-approved drug. PeptideHelper.org catalog status: Prescription.

What level of evidence supports hCG?

The current evidence base for hCG is best characterised as: FDA-Approved. See the methodology page for the full evidence-tier rubric.

What side effects are reported for hCG?

Known concerns reported in the literature for hCG include: Ovarian hyperstimulation syndrome (OHSS); thromboembolism; gynecomastia (males at high dose); arterial-thrombosis case reports; contraindicated in suspected/confirmed prostate or other androgen-dependent neoplasia; precocious puberty risk in pediatric use. Always consult a qualified clinician before any human use.

Is there anyone who should not use hCG?

hCG is FDA-approved, but no contraindications section was retrievable from its current label, so none is reproduced here. Consult the prescribing information and a qualified clinician before any human use.

How does hCG work?

The mechanism of action reported for hCG in the literature: LH-receptor agonist with minor FSH-like activity; in males stimulates testicular Leydig cells to produce endogenous testosterone; in females maintains corpus luteum progesterone production and triggers ovulation.

What is hCG studied for?

hCG has been studied in the published literature for: FDA-approved: female anovulatory infertility / ovulation induction; prepubertal cryptorchidism; selected hypogonadotropic hypogonadism. Off-label clinical use: intratesticular testosterone preservation during exogenous-T therapy; spermatogenesis restoration; HPG restart-stack protocols. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.

What is hCG?

hCG is classified as: Placental glycoprotein hormone (FDA-approved); LH-receptor agonist. Also known as: Human chorionic gonadotropin; Pregnyl; Novarel; Ovidrel (recombinant choriogonadotropin alfa).

Research focus area

All peptides studied for Sexual-Health, ranked by evidence tier and regulatory status.

Primary sources

  1. FDA Pregnyl (chorionic gonadotropin for injection, USP) prescribing information
  2. Coviello AD et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab 2005. PMID 15713727
  3. Ludwig M et al. Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril 2003. PMID 12738494
  4. Liu D et al. Impact of Deoxynivalenol, Cytokines, and Particulate Matter on Human Trophoblast Cells. International journal of molecular sciences 2026. PMID 42511775
  5. Nam Y et al. Changes in Ras and Ras-Associated GTPases During Maturation of Porcine Cumulus Cells and Oocytes. Animals : an open access journal from MDPI 2026. PMID 42511004
  6. Stavros S et al. Empty Follicle Syndrome: Current Therapeutic Approaches and the Role of Triggering Agents in Assisted Reproductive Technology. Medical sciences (Basel, Switzerland) 2026. PMID 42506338
  7. Shintani H et al. Primary Extragonadal Choriocarcinoma Presenting with Pneumothorax in an Elderly Male Patient: A Case Report. Case reports in oncology 2026. PMID 42488731
  8. Yu W et al. Ultrasensitive and rapid detection of botulinum neurotoxin serotype A via Argonaute-mediated signal cascade with a pregnancy test strip readout. Food chemistry 2026. PMID 42468431
  9. Mabrouk M et al. Lugol's Iodine as a Key Treatment in Transient Gestational Thyrotoxicosis: A Case Report. Case reports in endocrinology 2026. PMID 42466308
  10. Rahbar M et al. Elevated beta-human chorionic gonadotropin levels in a patient with end-stage renal disease awaiting kidney transplantation: a case report. Journal of medical case reports 2026. PMID 42050697
  11. Luo Q et al. Placental mesenchymal dysplasia: diagnostic and management insights from a case report and literature review. Archives of gynecology and obstetrics 2026. PMID 42049980
  12. Chen L et al. Development of machine learning models for predicting early pregnancy outcomes based on β-hCG, progesterone, and estradiol. PloS one 2026. PMID 42044144
  13. Çakır BT et al. Evaluation of Inflammatory Markers, First-Trimester Biochemical Tests, and Gelsolin Levels in Patients With Second-Trimester Pregnancy Loss. American journal of reproductive immunology (New York, N.Y. : 1989) 2026. PMID 42084712
  14. Han Q et al. Single-molecule force spectroscopy discovers a dual-binding mode in the hCG-mediated activation of LHCGR. Protein science : a publication of the Protein Society 2026. PMID 42010823
  15. Huang D et al. Reverse-Phase High-Performance Liquid Chromatography/Mass Spectrometry (RP-LC-MS/MS, Label-Free Method) for Component Analysis of Gonadotropin Drugs. Journal of mass spectrometry : JMS 2026. PMID 41952441
  16. Dankó I et al. Correlations of Free Beta Human Chorionic Gonadotropin/Pregnancy-Associated Plasma Protein A Ratio, Pregnancy Characteristics and Placental Pathology in Fetal Growth Restriction. Medical principles and practice : international journal of the Kuwait University, Health Science Centre 2026. PMID 42574290
  17. Yu H et al. Luteinizing hormone regulates seasonal steroidogenesis locally in the prostate of the muskrat (Ondatra zibethicus). The Journal of steroid biochemistry and molecular biology 2026. PMID 42567415
  18. Toner JP et al. Can a focus on intracellular signaling assist us with ovarian stimulation in poor-prognosis patients?. Fertility and sterility 2026. PMID 42155917
  19. Tespio G et al. Technical note: Development of a UHPLC-MS/MS method for the analysis of hCG and IGF-I from dried blood spots: A preliminary study. Forensic science international 2026. PMID 42385550
  20. Dual Trigger VS HCG Trigger for Final Oocyte Maturation in Normal Responders [NCT07861399 NA RECRUITING]
  21. hCG Treatment for Rehabilitation From a TBI [NCT07557615 EARLY_PHASE1 NOT_YET_RECRUITING]
  22. Verapamil In Preclinical Type 1 Diabetes [NCT07880769 PHASE2/PHASE3 NOT_YET_RECRUITING]
  23. A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) [NCT07340827 PHASE3 RECRUITING]
  24. Puangjit N et al. Potential effect of human chorionic gonadotropin-induced extracellular vesicle RNAs on mouse ovarian granulosa cells. FEBS open bio 2026. PMID 43018074
  25. Dieckmann KP et al. False-Positive Elevation of Serum Levels of Human Chorionic Gonadotropin (hCG) Evoked by Dietary Supplements in a Patient With Testicular Seminoma-A Case Report. Clinical case reports 2026. PMID 43011507
  26. Kumar N et al. Association and limited predictive performance of first-trimester PAPP-A, free β-hCG, and nuchal translucency for adverse neonatal outcomes: Prospective cohort study. Journal of neonatal-perinatal medicine 2026. PMID 43037620

Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.

Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.

Loading interactive view…